Progress of CD19-targeted therapy for acute B-lymphoblastic leukemia
10.3760/cma.j.cn115356-20221123-00334
- VernacularTitle:靶向CD19治疗急性B淋巴细胞白血病的研究进展
- Author:
Xiusong HUANG
1
;
Ke YANG
;
Youjiang TAN
;
Kaiming CHEN
;
Caiwen DUAN
Author Information
1. 右江民族医学院附属医院临床病理诊断与研究中心，百色 533000
- Keywords:
CD19;
Acute B-lymphocyte leukemia;
Monoclonal antibody;
Bispecific antibody;
Antibody drug conjugate;
Chimeric antigen receptor cells
- From:
Journal of Leukemia & Lymphoma
2024;33(6):373-377
- CountryChina
- Language:Chinese
-
Abstract:
Acute B-lymphoblastic leukemia (B-ALL) is the most common type of acute lymphoblastic leukemia. Chemotherapy is the main treatment for most patients, but there are serious side effects. CD19 is generally highly expressed in B-lineage malignancies and plays a key role in B cell signal transduction, activation and development. Therefore, it has become one of the effective targets for treatment of B-cell malignancies. At present, a variety of therapies targeting CD19 have been developed, including antibody drug conjugates, monoclonal antibodies, bispecific antibodies and chimeric antigen receptors cell therapies. This paper reviews the clinical trial progress of CD19-targeted therapy for B-ALL.
